Replimune combines a bullish analyst-cluster catalyst with a name that has already run past its target, sub-floor quality, cash burn, and extremely high short interest, leaving a binary clinical outcome as the main swing factor for the stock.
Thesis pillars
- Analyst Cluster Catalyst→Stable
- Quality Below Floor Cash Burn→Stable
- Momentum Gate Failure→Stable
- +2 more pillars — see the Why tab for full reasoning
Replimune Group, Inc. (REPL) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $11.60: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.8/10. Specifically: High short interest: 50%; Below-average business quality; Rich valuation.
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies built on its proprietary RPx platform, an engineered herpes simplex virus 1 (HSV-1) backbone designed to kill tumors directly and trigger a systemic anti-tumor immune response. The company... Read more
Sell if holding. Engine safety override at $11.60: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.8/10. Specifically: High short interest: 50%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 3.8/10, high confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 32d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
About Replimune Group, Inc.
About Replimune Group, Inc.
Replimune's lead product candidate, RP1, combined with Bristol Myers Squibb's nivolumab, has not yet reached the market: the FDA issued a first complete response letter in July 2025 and a second in April 2026 on the Biologics License Application for advanced melanoma, before accepting a Class 1 resubmission in June 2026 with an August 2, 2026 target action date. Replimune has generated no product revenue to date and expects an FDA advisory committee meeting in late July 2026.
Replimune operates an in-house manufacturing facility for its viral product candidates while relying on third-party collaborators for the checkpoint-blockade drugs used in combination therapy — Bristol Myers Squibb's nivolumab for RP1 and RP2 trials, Regeneron's cemiplimab under a separate collaboration, and Roche's atezolizumab and bevacizumab for a hepatocellular carcinoma signal-finding study. Beyond the melanoma-focused IGNYTE and I-3 trials for RP1, the company is advancing RP2 in metastatic uveal melanoma through the randomized Phase 2/3 REVEAL study, while RP3 development has been deprioritized. Replimune has generated no revenue from product sales and continues to fund clinical development from its cash resources, competing against other biopharmaceutical and biotechnology companies pursuing checkpoint-blockade combination approaches.
Show full overview
Replimune's regulatory setbacks illustrate concentrated pipeline risk rather than a diversified product base: the FDA's two complete response letters on the RP1 BLA both centered on the same underlying concern — that the pivotal IGNYTE trial's patient-population heterogeneity undermined its ability to serve as adequate and well-controlled evidence of effectiveness. Because RP2, RP3, and every other candidate in Replimune's pipeline are built on the same proprietary RPx platform as RP1, a platform-level manufacturing or safety problem, not just an RP1-specific trial-design dispute, could stall the entire portfolio at once rather than just the melanoma program.
See also: Healthcare · Biotechnology
From Replimune Group, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-07Recent Developments — Replimune Group, Inc.
Latest news
- NEWS Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga Jun 30, 2026 neutral
Generated 2026-07-07T13:21:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineRPx platform10-K Item 1A: 'all of the product candidates in our current pipeline are based on our proprietary RPx platform ... we may be required to discontinue development of all product candidates'
- HIGHSupplierBMS nivolumab supply10-K Item 1A: 'We have entered into agreements with BMS for the supply of nivolumab, its anti-PD-1 therapy, for use in connection with our ongoing IGNYTE Phase 1/2 trials with RP1'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.60: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.8/10. Specifically: High short interest: 50%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $10.67. Score 3.8/10, high confidence.
Take-profit target: $12.25 (+6.8% upside). Prior stop was $10.67. Stop-loss: $10.67.
Concentration risk — Pipeline: RPx platform; Concentration risk — Supplier: BMS nivolumab supply; Target reached (-19.1% upside).
Replimune Group, Inc. trades at a P/E of N/A (forward -10.0). TrendMatrix value score: 3.0/10. Verdict: Sell.
14 analysts cover REPL with a consensus score of 3.7/5. Average price target: $11.
What does Replimune Group, Inc. do?Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies built on its proprietary RPx...
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies built on its proprietary RPx platform, an engineered herpes simplex virus 1 (HSV-1) backbone designed to kill tumors directly and trigger a systemic anti-tumor immune response. The company has not generated any product revenue and depends on its lead candidate, RP1, combined with Bristol Myers Squibb's nivolumab, which received two FDA complete response letters (July 2025 and April 2026) before the FDA accepted a Class 1 BLA resubmission with an August 2, 2026 target action date.